Trovan (trovafloxacin), a broad-spectrum antibiotic, has been approved for the treatment of 14 bacterial infections.
In June of 1999 the Food and Drug Administration issued a public health advisory to physicians concerning the risks of liver toxicity associated with the use of Trovan (trovafloxacin, an oral antibiotic) and Trovan-IV (alatrofloxacin, the intravenous formulation of the drug). This action followed postmarketing reports of rare but severe liver injuries leading to transplants and deaths. The drug was subsequently discontinued.
Trovan is a member of the quinolone class of antibiotics.